LEASELease • February 27th, 2018 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances)
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Double asterisks denote omissions. SUPPLY AGREEMENTSupply Agreement • February 27th, 2018 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS SUPPLY AGREEMENT (the “Agreement”) is entered into as of this 24th day of January, 2018 (the “Effective Date”), by and between Spark Therapeutics, Inc., a Delaware corporation organized under the laws of the State of Delaware, having a principal place of business at 3737 Market Street, Suite 1300, Philadelphia, PA 19104, USA (“Spark”), and Novartis Pharma AG, a Swiss company, with offices at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”). Spark and Novartis are sometimes referred to herein each as a “Party” and collectively as the “Parties”.
LICENSING AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN SPARK THERAPEUTICS, INC. AND NOVARTIS PHARMA AG January 24, 2018Licensing Agreement • February 27th, 2018 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Licensing and Commercialization Agreement (“Agreement”) is entered into as of January 24, 2018 (the “Effective Date”) by and between Spark Therapeutics, Inc., a Delaware corporation, with offices at 3737 Market Street, Suite 1300, Philadelphia, PA 19104, USA (“Spark”) and Novartis Pharma AG, a Swiss company, with offices at Lichtstrasse 35, CH-4056 Basel, Switzerland (“Novartis”).
AMENDMENT #2 TO LICENSE AGREEMENTLicense Agreement • February 27th, 2018 • Spark Therapeutics, Inc. • Biological products, (no disgnostic substances)
This Amendment #2 to License Agreement (the “Second Amendment”) is entered into and made effective as of November 6, 2017 (the “Second Amendment Effective Date”) and amends that certain License Agreement dated December 6, 2014 (as previously amended by the First Amendment dated June 9, 2016, the “License Agreement”), by and between Pfizer Inc., a corporation organized and existing under the laws of the State of Delaware with offices at 235 East 42nd Street, New York, New York 10017 (“Pfizer”) and Spark Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware with offices at 3737 Market Street, Suite 1300, Philadelphia, Pennsylvania 19104 (“Spark”). Pfizer and Spark are referred to herein individually as a “Party” and collectively as the “Parties”.
